CHT101

Phase 1Small molecule

TTianjin Medical University Cancer Institute and Hospital

CHT101 is one of 102 small molecule programs targeting Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

101

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumorsRecruiting

Hematological MalignanciesRecruiting

Refractory Solid TumorsNot yet recruiting

Advanced Solid TumorsPhase 1

Recruiting

Hematological MalignanciesPhase 1

Recruiting

Refractory Solid TumorsPhase 1

Not yet recruiting

Competition

Competitive Landscape

286 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

24 2

Fludara

Sanofi

Phase 2

15 3

Paraplatin

AAvyxa

Phase 2

31 4

Taxotere

AAvyxa

Phase 2

23 5

Erbitux

IImclone

Phase 2

14 6

Tagrisso

AstraZeneca

Phase 2

3 7

Libtayo

Regeneron

Phase 2

3 8

Alimta

SShawn Eagle

Phase 2

12 9

PENPULIMAB KCQX

AAkeso

Phase 2

2 10

Navmi

SSummit Therapeutics

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Hematological Malignancies

NCT06914037

Q4 2028

Phase 1Not yet recruiting

Hematological Malignancies

NCT07809126

Phase 1Not yet recruiting

Hematological Malignancies

NCT07809139

Q2 2029

Phase 1Not yet recruiting

Refractory Solid Tumors

NCT06383507

Q2 2039

Phase 1Recruiting

Advanced Solid Tumors

NCT06730659

Clinical

Trials by Indication[1]

Hematological Malignancies3 trials

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT06914037·24 enrolled

A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies

Not yet recruiting·NNanjing Miracle Biotechnology Co., Ltd.·Phase 1·NCT07809126·30 enrolled

A Phase I, Single-Arm, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies

Not yet recruiting·NNanjing Miracle Biotechnology Co., Ltd.·Phase 1·NCT07809139·30 enrolled

Refractory Solid Tumors1 trial

A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors

Not yet recruiting·ZZhejiang University·Phase 1·NCT06383507·18 enrolled

Advanced Solid Tumors1 trial

A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT06730659·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for CHT101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHT101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHT101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Medical University Cancer Institute and Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TTianjin Medical University Cancer Institute and Hospital

CHT101

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Q2 2029

Q2 2039

Trials by Indication[1]

Hematological Malignancies3 trials

Refractory Solid Tumors1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News